A new analysis for heart failure drug Entresto revealed novel insights for managing diabetes when compared to an older medication.
One area targeted for drastic downsizing is agencies performing government-funded science research, including the National Institutes of Health (NIH).
These late-stage study results were presented in Washington D.C. at the annual American College of Cardiology meeting.
An experimental treatment for clostridium dificile infections is getting a second chance.
The project, called the Asthma Mobile Health Study, launched in March 2015.
The financing will help Spero Therapeutics further advance its assets into the different stages of clinical testing.
The company will work with Editas Medicine, a biotech backed by Bill Gates and Google.
The fallout from Mylan’s EpiPen pricing controversy appears to be taking a toll, according to a new analysis.
GlaxoSmithKline could maintain its edge in the respiratory disease treatment space.
Eli Lilly’s grip on the psoriasis treatment space could be getting stronger.
Detailed information regarding these trials were presented at the annual American Academy of Dermatology Meeting in Orlando, Florida.
Researchers are moving closer to refining a novel gene therapy for slow heartbeats.
Johnson & Johnson plans on releasing annual reports containing this information going forward.
Pfizer is getting closer to gaining regulatory approval for an investigational leukemia treatment called inotuzumab ozogamicin.
British-based pharmaceutical firm AstraZeneca may be gaining an advantage in the burgeoning PARP inhibitor drug space.
Boston-based Rhythm Pharmaceuticals obtained a new round of funding to help continue development of its lead peptide therapy setmelanotide.
A promising multiple sclerosis treatment called Ocrevus will play a crucial role in this growth.
Investigators will gain a five-year appointment and up to $1.5 million in funding to kick start their research projects.
Another drug company reignited the debate over appropriate pricing policies for important medications.
More than 150 biotech CEOS, venture capitalists and startup founders signed a letter to the President expressing their deep concern and opposition to the order.
British-based GW Pharmaceuticals received more good news regarding its cannabis-based drug development efforts.
Investigators running this randomized, double-blind, placebo-controlled trial recruited 150 elderly patients diagnosed with acute myeloid leukemia.
Bristol-Myers Squibb’s prized immuno-oncology drug gained another label expansion.
Another drug company unveiled a new strategy for dealing with the drug pricing debate.
The government is working on new strategies to ensure pharmaceutical and biotech R&D can thrive in the country after the process is completed.
The lobbying group began laying the groundwork for this program several months ago in the midst of the election.
Celgene expanded its autoimmune disease pipeline with a new acquisition.
MDX has traversed a difficult path during the research and development process.
President-elect Donald Trump went after the pharmaceutical industry in the opening remarks of his first press conference since the election.
The Cambridge, Massachusetts-based biotech company has kept its pipeline a secret until now.
Japanese drugmaker Takeda acquired Boston-based Ariad Pharmaceuticals, a biotech company specializing in cancer drugs.
The biotech startup wants to use this new funding to advance development of its specialized early detection cancer test.
The Foster City, California-based biotech added a top cancer specialist to its executive ranks.
An analysis published by Deloitte’s Centre for Health Solutions indicated the pharmaceutical industry experienced a continued decline in R&D returns for...
Other researchers have used similar methods to sift through large amounts of data in order to pinpoint promising compounds to treat diseases.
These articles provide a snapshot of the change the pharmaceutical industry experienced throughout the year.
A new report explains how hospitals are implementing aggressive new measures to cut pharmaceutical spending in the face of rapidly rising prices for certain...
Novartis is bolstering its dermatology portfolio with a new acquisition.
Voyager Therapeutics is testing an experimental gene therapy that could boost Parkinson’s patients’ responses to levodopa.